4 March 2019

Invitation to comment

The Department of Health is seeking comments from interested parties on the terms of reference for the Review of the Narcotic Drugs Act 1967 (the ND Act):

  1. The efficiency and effectiveness of the structure of the licensing and permit regimes and other restrictions in the Act in controlling the supply of narcotic drugs and options to reduce the regulatory burden on affected parties, whilst still achieving the object of the ND Act.
  2. The efficiency and effectiveness of the obligations in the Act relating to the provision of information and other administrative requirements and options for reducing the regulatory burden on affected parties, whilst still achieving the object of the ND Act.
  3. The appropriateness of the compliance and enforcement regime in the ND Act, including in relation to the Secretary's functions and powers.

The primary focus of the Review is on the regulatory framework for the cultivation, production and manufacture of medicinal cannabis under the ND Act. Interest parties can find further information, including in relation to key themes, specific issues and examples of matters that do not fall within the scope of the review in the Discussion paper.

Consultation documents

Discussion paper: Review of Narcotic Drugs Act 1967 - PDF 313KB

Discussion paper: Review of Narcotic Drugs Act 1967 - DOCX 221KB

Timetable

Discussion paper released for consultation on Monday, 4 March 2019.

Submissions close at 5:00pm on Tuesday, 2 April 2019.

About the consultation

The Review is required to invite public submissions, to conduct targeted consultations with interested stakeholders and through public forums, and to consult the Australian Advisory Council on the Medicinal Use of Cannabis. Three public consultation forums have been held:

  • Sydney - 5 February 2019
  • Brisbane - 6 February 2019
  • Melbourne - 8 February 2019.

The public forums enabled interested parties to raise issues that could be considered in the review.

The Discussion Paper and invitation for written submissions continues the public consultation.

Content of submissions

Submissions may address any, or all, of the terms of reference identified above or the key themes and/or specific issues identified in the Discussion Paper.

The Review is particularly interested in hearing about your practical engagement with the medicinal cannabis scheme in the ND Act. We welcome examples and case studies of issues you have encountered. Concrete proposals for legislative and administrative reform are also invited.

If you are unsure whether a topic or issue fits within the Terms of Reference, the Review invites you to email the Review Secretariat at ReviewNarcoticDrugsAct@health.gov.au, or call us on 1800 020 653, seeking clarification. The Secretariat will endeavour to respond as soon as possible.

How to submit

Complete the online consultation submission form to upload your submission in either pdf or word format.

Consultation submission form

Alternatively, hardcopy submissions with a printed cover sheet may be mailed to:

Narcotic Drugs Act Review Secretariat
Health Products Regulation Group
Australian Government Department of Health
PO Box 100 Woden ACT 2606

Print version: Consultation submission cover sheet - DOCX 42kb

Enquiries

Any questions relating to submissions should be directed to the Review Secretariat by email to ReviewNarcoticDrugsAct@health.gov.au or by telephone to 1800 020 653.

What will happen

All submissions will be placed on this website unless marked confidential or indicated otherwise in the submission form (see Privacy information).

The final report in the Review is to be tabled in both Houses of Parliament by 29 October 2019.

Privacy information

All submissions will be placed on this website unless marked confidential or indicated otherwise in the submission form. Please note that the Review collects your personal information in this submission in order to:

  • contact you if the Review wants to seek clarification of issues raised in your submission or to check whether you consent to certain information that you have provided being made publicly available;
  • help provide context about your submission (e.g. to determine whether you are an individual or a director of a company or representing an interest group); and/or
  • Seek feedback about how the consultation was undertaken.

Please do not include personal information about other individuals in the body of your submission. The Review notes that personal information in this context means information or an opinion about an individual whose identity is apparent, or can reasonably be ascertained, from the information or opinion.

More information on privacy can be found on our website.